Literature DB >> 8383008

A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.

A Y Chen1, C Yu, A Bodley, L F Peng, L F Liu.   

Abstract

Hoechst dye 33342 (Ho33342), like many other DNA minor groove binding ligands and its parent compound Hoechst dye 33258 (Ho33258), nonspecifically inhibits the catalytic activities of many DNA enzymes. However, both Ho33258 and Ho33342 also specifically interrupt the breakage/reunion reaction of mammalian DNA topoisomerase I by trapping reversible topoisomerase I cleavable complexes. The enhanced membrane permeability of Ho33342 over its parent compound Ho33258 has allowed studies of the cellular action of Ho33342. Our results suggest that Ho33342 also traps topoisomerase I but not topoisomerase II into reversible cleavable complexes in human KB cells. Although Ho33342 shares a similar mechanism of action with camptothecin, a prototypic topoisomerase I poison, in trapping topoisomerase I cleavable complexes, Ho33342 differs from camptothecin in its effect on drug-resistant cells. Different from camptothecin, Ho33342 was shown to be about 200-fold less cytotoxic in MDR1-overexpressing human KB V1 cells relative to parental human KB 3-1 cells. Ho33342 is only 5-fold less cytotoxic for camptothecin-resistant CPT-K5 cells, which expresses a highly camptothecin-resistant from of topoisomerase I, than for the wild type human lymphoblast RPMI 8402 cells. Our studies suggest a potential use of Hoechst 33342 as a new topoisomerase I poison in antitumor chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383008

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.

Authors:  Maurish Bukhari; Han Deng; Noelle Jones; Zachary Towne; Craig D Woodworth; Damien S K Samways
Journal:  FEBS Lett       Date:  2015-05-01       Impact factor: 4.124

2.  Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells.

Authors:  Jean-François Mayol; Corinne Loeuillet; Francis Hérodin; Didier Wion
Journal:  Bioessays       Date:  2009-09       Impact factor: 4.345

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning.

Authors:  D S Pilch; Z Xu; Q Sun; E J LaVoie; L F Liu; K J Breslauer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 6.  Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain.

Authors:  P L Golden; W M Pardridge
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

7.  Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes.

Authors:  Joshua E Allen; Lori S Hart; David T Dicker; Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-11-27       Impact factor: 4.742

8.  Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles.

Authors:  Nihar Ranjan; Geraldine Fulcrand; Ada King; Joseph Brown; Xiuping Jiang; Fenfei Leng; Dev P Arya
Journal:  Medchemcomm       Date:  2014-06-01       Impact factor: 3.597

9.  Induction of DNA damage response by the supravital probes of nucleic acids.

Authors:  Hong Zhao; Frank Traganos; Jurek Dobrucki; Donald Wlodkowic; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2009-06       Impact factor: 4.355

10.  3,4-dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I.

Authors:  Sandhya Bansal; Devapriya Sinha; Manish Singh; Bokun Cheng; Yuk-Ching Tse-Dinh; Vibha Tandon
Journal:  J Antimicrob Chemother       Date:  2012-09-03       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.